Trump to Expand Discount Drug Pricing, Says White House Official

• TrumpRx.gov was originally launched in January as part of pricing agreements with pharmaceutical companies to reduce drug costs
• Despite Trump's pledge to make prescription drugs cheaper in the U.S. than anywhere else, a Reuters analysis found prices on the website are not lower than those in the United Kingdom
• Mark Cuban's Cost Plus Drugs, which already sells discounted medicines directly to consumers, will apparently play a role in the expanded program

Summary: Trump to Expand Discount Drug Pricing Program

Key Development:

President Donald Trump will announce a major expansion of TrumpRx.gov on Monday, May 18, 2026, adding generic medications to the government-backed prescription drug discount website, according to White House officials.

Program Details:

• TrumpRx was initially launched in January 2026 as part of Trump's "most-favored-nation" deals with pharmaceutical manufacturers
• The program aims to reduce U.S. prescription drug costs to levels comparable with other developed nations
• Billionaire Mark Cuban, who operates Cost Plus Drugs online pharmacy selling discounted medicines, is expected to attend the White House announcement

Market Context:

The expansion represents the administration's continued push to lower healthcare costs for Americans. However, despite Trump's pledge to make prescription drugs cheaper in the U.S. than anywhere globally, a Reuters price comparison reveals that TrumpRx pricing still does not undercut costs in the United Kingdom.

Implications:

• Pharmaceutical companies may face continued pricing pressure from government initiatives
• The partnership with Cuban's Cost Plus Drugs platform could signal broader public-private collaboration in the discount drug space
• Generic drug manufacturers may see increased competition through government-backed distribution channels
• The program's effectiveness remains questionable given its failure to achieve lower-than-international pricing on current offerings

Sector Impact:

This development affects pharmaceutical manufacturers, pharmacy benefit managers, and retail pharmacies, potentially disrupting traditional drug pricing and distribution models in the U.S. healthcare market.